Catalyst
Slingshot members are tracking this event:
Seattle Genetics to report additional data from a Phase 1 trial of 33A in combination with HMAs at the European Hematology Association (EHA) annual meeting being held June 9 to 12, 2016 in Copenhagen, Denmark
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGEN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 11, 2016
Occurred Source:
http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2176948
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Hypomethylating Agents, 33a, Vadastuximab Talirin, Phase 1, Additional Data
